IMA Chandigarh welcomes you to recorded webinar session on “Treating Mild to Severe COVID-19 Patients”
What was covered:
Introduction of panelist: Dr. Mayuri Keskar, MLH & TC4A
Welcome note: Dr Vanita Gupta and Dr Nitin Mathur, started the webinar with a welcome note, they addressed the participants with the COVID situation in Chandigarh state and how the HCP are dealing with it.
Discussion on:
Treating mild to moderate cases of COVID with use of Favipiravir - (Dr Surendra Gupta) Dr Gupta started his session by discussing the COVID situation around the globe, then he defined mild, moderate and severe cases. He also explained about herd immunity. The session then continued with different treatment options available. Dr Gupta explained about the pharmacology of Favipiravir and the different clinical trials done till date.
Treating moderate to severe COVID cases with use of Remdesivir - (Dr S.K. Jindal) Dr Jindal continued the session. He shared detailed explanations about mild to moderate cases of COVID-19, the symptomatology with vital parameters monitoring and the different lab diagnosis. He then explained about the treatment part, and use of antiviral in COVID cases. Dr Jindal explained about the Remdesivir its use and the clinical trials on the drug
Panel discussion with Q&A session: After the speaker’s session, panel discussion started followed by Q&A session. The panel shared their experiences answering the questions and answers. Almost all questions were addressed by the speakers
Vote of thanks and Poll: At the end of the webinar Dr Mayuri raised the poll questions for attendees and shared vote of thanks with IMA Chandigarh to provide the opportunity to co host the webinar with them. MLH team also thanked respected speakers and moderator for providing their valuable time for sharing their experience in treating COVID-19 and Mylan Pharmaceuticals to make this series of COVID-19 webinars possible.
